Contenu disponible en anglais seulement.
Bulletin de la Bourse
IntelGenx Technologies Corp. (IGX, IGX.WT, IGX.DB) inscrit à la Bourse de Toronto
5 octobre 2021
Issuer: IntelGenx Technologies Corp. (the "Company")
| Security | Symbol | Issued and Outstanding Securities | Reserved Securities | Trading Currency |
|---|---|---|---|---|
| Common shares ("Shares") | IGX | 150,627,762 | 93,427,229 | CDN$ |
| Share Purchase Warrants ("Warrants") | IGX.WT | 16,317,000 | 0 | CDN$ |
| 8% Convertible Unsecured Subordinated Debentures ("Debentures") | IGX.DB | $7,011,000 | 0 | CDN$ |
| Listing category: | Industrial, Non-Exempt Issuer |
| Trading currency: | CDN$ |
| Listing and posted for trading date: | October 7, 2021 (at the opening) |
| Other market(s): | The Shares have been listed on TSX Venture Exchange (the "TSXV") since May 23, 2008. The Warrants have been listed on the TSXV since February 13, 2020. The Debentures have been listed on the TSXV since July 12, 2017. The aforementioned securities will be delisted from the TSXV on October 7, 2021, upon commencement of trading on ÍÃ×ÓÏÈÉú ("TSX"). |
| Temporary market maker: | W.D. Latimer Co. Ltd. |
| Security ownership registration: | DTCC Direct Registration System for the Shares, Non certificated Issue for the Warrants and CDS Book Entry only for the Debentures |
| Investor relations: | André Godin President and Chief Financial Officer (514) 313-7440 Ext 203 Email: andre@intelgenx.com - or – Stephen Kilmer IR Consultant (647) 872-4849 Email: stephen@kilmerlucas.com |
| Incorporation: | Delaware, United States |
| Fiscal year end: | December 31 |
| Nature of business: | The Company is a drug delivery company. The Company's focus is on the development and manufacturing of novel oral thin film products for the pharmaceutical market. The Company also offers partners a comprehensive portfolio of pharmaceutical services, including pharmaceutical research and development, clinical monitoring, regulatory support, tech transfer, manufacturing scale-up and commercial manufacturing. |
| Transfer agent and registrar: | TSX Trust Company at its principal office in Toronto as co-transfer agent and registrar for the Shares and as transfer agent and registrar for the Warrants and Debentures. |
| Dividends: | The Company does not anticipate paying cash dividends on the Shares in the foreseeable future. |
| Sponsorship: | Not applicable |
Principal Terms of the Warrants
| Exercise price: | $0.75 per Share |
| Expiry: | February 11, 2023 (at 5:00 p.m. (Toronto time)) |
| Additional information: | Warrant indenture dated February 11, 2020 which is available at . Capitalized terms not otherwise defined herein are as defined in the warrant indenture. |
Principal Terms of the Debentures
| Trading rules: | The Debentures will not trade or be quoted on an accrued interest basis (i.e. they will trade and be quoted on an interest flat basis) as a result of the Company's ability to elect, from time to time, to satisfy all or any part of its interest obligation on the Debentures on any Interest Payment Date by issuing and delivering Freely Tradeable Common Shares to such holders of Debentures as detailed in the trust indenture between the Company and TSX Trust Company dated July 12, 2017 (the "Indenture"). All bids, offers and trades in the Debentures must reflect both the capital portion of the Debentures and all accrued interest. TSX will not report accrued interest in regard to any trade in the Debentures made through the facilities of TSX. The Debentures, which are issuable in the minimum principal amount of $1,000 each, will be quoted based on $100 principal amounts with all trades being made in multiples of $1,000. The minimum trading unit of Debentures is $1,000 and a board lot of Debentures is $1,000. |
| Maturity date: | June 30, 2022 |
| Interest payment dates: | Semi-annually on June 30 and December 31 |
| Interest rate: | 8% per annum. Interest will be computed on the basis of a 365-day year. |
| Next interest payment date: | December 31, 2021 |
| Next interest payment amount: | $40.00 per $1,000 principal amount |
| Conversion: | Debentures are convertible into Shares, at a price of $0.50 per Share. |
| Additional information: | Second supplemental trust indenture dated June 25, 2020 to Indenture which are available at . Capitalized terms not otherwise defined herein are as defined in the trust indentures. |
| TSX contact: | Chris Birkett, Managing Director, ÍÃ×ÓÏÈÉú |